title: Adalimumab in Crohn's disease.
abstract: Although the advent of infliximab has changed the treatment paradigm and goals in inflammatory bowel diseases (IBD), it does not provide a cure for IBD and recent evidence has demonstrated that the immunogenicity of this chimeric anti-TNF antibody is associated with secondary loss of response and intolerance. In ulcerative colitis (UC) the efficacy of infliximab was demonstrated in two large clinical trials, but long-term maintenance efficacy data are lacking. Novel biological agents have entered clinical development and pioneering trials have been reported in the last two years. For Crohn's disease (CD) two anti-TNF agents, the fully human IgG1 anti-TNF monoclonal adalimumab and the humanized pegylated Fab-fragment certolizumab-pegol and the humanized anti alpha4 integrin IgG4 antibody both have demonstrated efficacy as maintenance agents. Adalimumab has been approved to treat active rheumatoid arthritis, psoriatric arthritis, and ankylosing spondylitis, and recently moderate-to-severe luminal CD has been added as an indication for this agent both by the FDA and EMEA. Further evidence is needed to establish the therapeutic potential of adalimumab in fistulizing CD and in UC. The benefit to risk ratio of anti-TNF agents in refractory IBD is clearly positive and since most of the toxicity is class specific, adalimumab is expected to have a safety profile similar to that of infliximab except for adverse events related to infusions.
authors.affiliation: Division of Gastroenterology, University of Leuven, Leuven, Belgium.
authors.forename: Gert
authors.initials: G
authors.lastname: Van Assche
authors.forename: Séverine
authors.initials: S
authors.lastname: Vermeire
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93
references.pmid: 16797249
references.citation: Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53
references.pmid: 15224278
references.citation: JAMA. 2006 May 17;295(19):2275-85
references.pmid: 16705109
references.citation: Inflamm Bowel Dis. 2004 Jul;10(4):333-8
references.pmid: 15475739
references.citation: Ann Rheum Dis. 2007 Jul;66(7):921-6
references.pmid: 17301106
references.citation: N Engl J Med. 2002 Aug 8;347(6):417-29
references.pmid: 12167685
references.citation: Gut. 1994 Mar;35(3):360-2
references.pmid: 8150347
references.citation: Inflamm Bowel Dis. 2007 Nov;13(11):1323-32
references.pmid: 17636564
references.citation: Arthritis Rheum. 2007 May;56(5):1433-9
references.pmid: 17469100
references.citation: World J Gastroenterol. 2007 Apr 28;13(16):2328-32
references.pmid: 17511032
references.citation: Clin Gastroenterol Hepatol. 2006 May;4(5):621-30
references.pmid: 16678077
references.citation: N Engl J Med. 1999 May 6;340(18):1398-405
references.pmid: 10228190
references.citation: N Engl J Med. 2007 Jul 19;357(3):239-50
references.pmid: 17634459
references.citation: Methods. 2005 May;36(1):3-10
references.pmid: 15848070
references.citation: N Engl J Med. 2007 Jul 19;357(3):228-38
references.pmid: 17634458
references.citation: Gastroenterology. 2007 Jan;132(1):52-65
references.pmid: 17241859
references.citation: Am J Gastroenterol. 2004 Oct;99(10):1984-9
references.pmid: 15447761
references.citation: Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18
references.pmid: 17269996
references.citation: Gut. 2005 May;54(5):617-22
references.pmid: 15831904
references.citation: Gut. 2002 Feb;50(2):206-11
references.pmid: 11788561
references.citation: N Engl J Med. 2003 Feb 13;348(7):601-8
references.pmid: 12584368
references.citation: Gastroenterology. 2001 Nov;121(5):1145-57
references.pmid: 11677207
references.citation: Arthritis Rheum. 2005 Nov;52(11):3403-12
references.pmid: 16255017
references.citation: Gastroenterology. 2002 Jan;122(1):7-14
references.pmid: 11781274
references.citation: Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22
references.pmid: 15852250
references.citation: Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
references.pmid: 16472588
references.citation: Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S194-8
references.pmid: 15983899
references.citation: Gastroenterology. 2006 Mar;130(3):650-6
references.pmid: 16530505
references.citation: Lancet. 2002 May 4;359(9317):1541-9
references.pmid: 12047962
references.citation: Ann Intern Med. 2007 Jun 19;146(12):829-38
references.pmid: 17470824
references.citation: Gastroenterology. 2003 Jul;125(1):32-9
references.pmid: 12851868
references.citation: N Engl J Med. 1997 Oct 9;337(15):1029-35
references.pmid: 9321530
references.citation: Ann Rheum Dis. 2006 Jul;65(7):889-94
references.pmid: 16439435
references.citation: Gastroenterology. 2005 Sep;129(3):807-18
references.pmid: 16143120
references.citation: N Engl J Med. 2001 Oct 11;345(15):1098-104
references.pmid: 11596589
references.citation: Inflamm Bowel Dis. 2006 Jan;12(1):22-8
references.pmid: 16374254
references.citation: Aliment Pharmacol Ther. 2001 Apr;15(4):463-73
references.pmid: 11284774
references.citation: Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8
references.pmid: 15691299
references.citation: Gastroenterology. 2003 Apr;124(4):917-24
references.pmid: 12671888
references.citation: Gut. 2007 Sep;56(9):1232-9
references.pmid: 17299059
references.citation: N Engl J Med. 2004 Feb 26;350(9):876-85
references.pmid: 14985485
references.citation: Gastroenterology. 2001 Nov;121(5):1088-94
references.pmid: 11677200
references.citation: Methods. 2005 May;36(1):61-8
references.pmid: 15848075
references.citation: Gastroenterology. 2004 Feb;126(2):402-13
references.pmid: 14762776
references.citation: Gut. 2004 Jan;53(1):70-7
references.pmid: 14684579
references.citation: Gastroenterology. 2003 Jun;124(7):1774-85
references.pmid: 12806611